Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
Authors
Emma C. Hulshof (ORCID: https://orcid.org/0000-0001-5994-6253)
Femke M. de Man (ORCID: https://orcid.org/0000-0001-7396-7050)
N. Heersche (ORCID: https://orcid.org/0000-0003-2913-8989)
Mirjam de With (ORCID: https://orcid.org/0000-0002-9953-7945)
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
Emma C. Hulshof, Femke M. de Man, N. Heersche, Mirjam de With et al.
Journal
The Lancet Regional Health - Europe
Topics
Cancer therapeutics and mechanisms
article
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
Emma C. Hulshof, Femke M. de Man, N. Heersche, Mirjam de With, Sander Bins, Ron H.J. Mathijssen, Maarten J. Deenen, Gelderblom Hans, Doortje T.M.M. Böhm, Miriam L Wumkes, Marije Joosse, Irene E.G. van Hellemond, Ron H.N. van Schaik, Brigitte C.M. Haberkorn, Anna M. Thijs, Arjan J. Verschoor, Qiong-Yi Wu, Sofía L.J. Peeters, Gysella Oomens, Aisha Osman, Stefan Böhringer, Henk-Jan Guchelaar, Roselien Guiljam
article en
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Regional Health - EuropeVol. 64
Institutions
Radboud University Nijmegen (NL), Leiden University Medical Center (NL), Catharina Ziekenhuis (NL), Reinier de Graaf Hospital (NL), Maasstad Ziekenhuis (NL), Erasmus MC Cancer Institute (NL), Jeroen Bosch Ziekenhuis (NL), Erasmus University Rotterdam (NL)